Plotkin Financial Advisors LLC Purchases New Holdings in Eli Lilly and Company (NYSE:LLY)

Plotkin Financial Advisors LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 954 shares of the company’s stock, valued at approximately $845,000.

Several other large investors have also recently added to or reduced their stakes in LLY. Massmutual Trust Co. FSB ADV increased its stake in Eli Lilly and Company by 9.8% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 3,534 shares of the company’s stock valued at $3,200,000 after buying an additional 315 shares during the period. Beese Fulmer Investment Management Inc. increased its stake in Eli Lilly and Company by 3.4% in the 2nd quarter. Beese Fulmer Investment Management Inc. now owns 604 shares of the company’s stock valued at $547,000 after buying an additional 20 shares during the period. HBW Advisory Services LLC increased its stake in Eli Lilly and Company by 40.6% in the 2nd quarter. HBW Advisory Services LLC now owns 917 shares of the company’s stock valued at $830,000 after buying an additional 265 shares during the period. ST Germain D J Co. Inc. increased its stake in Eli Lilly and Company by 109.4% in the 2nd quarter. ST Germain D J Co. Inc. now owns 2,693 shares of the company’s stock valued at $2,438,000 after buying an additional 1,407 shares during the period. Finally, Bank & Trust Co acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $11,133,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LLY. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Guggenheim increased their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Wolfe Research began coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Finally, Berenberg Bank increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $795.35 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The firm has a fifty day moving average price of $851.90 and a two-hundred day moving average price of $870.26. The company has a market cap of $755.04 billion, a PE ratio of 85.98, a price-to-earnings-growth ratio of 3.01 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period last year, the company earned $0.10 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.